MedTrace Logo

Anti-HIV Drugs for Ugandan Patients With HIV and Tuberculosis

NCT00078247 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2010-08-12

No results posted yet for this study

Summary

This study is designed to determine whether 6 months of anti-HIV drugs given along with tuberculosis treatment will delay the onset of AIDS in HIV infected African patients.

Conditions

Interventions

DRUG

Abacavir

300 mg tablet taken orally twice daily

DRUG

Lamivudine

300 mg tablet taken orally daily

DRUG

Zidovudine

300 mg tablet taken orally twice daily

DRUG

Tuberculosis treatment

Tuberculosis treatment

Sponsors & Collaborators

  • Makerere University

    collaborator OTHER

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Christopher C. Whalen, MD · Case Western Reserve University

  • Roy Mugerwa, MD · Makerere University

  • Diane Havlir, MD · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
13 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31

Countries

  • Uganda

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00078247 on ClinicalTrials.gov